Bivalirudin for anticoagulation in mechanical aortic valve replacement and heparin-induced thrombocytopenia

Moti Klein, Aaron Tomer, Andre Swartz, Leonid Koyffman, Natan Weksler

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Heparin-induced thrombocytopenia (HIT) is a potentially serious syndrome. Since there are some alternatives to treatment with heparin in patients who develop HIT, the decision as to which to use should be based on renal and hepatic function, drug availability and the available monitoring resources. We report a patient who received heparin for mechanical aortic valve replacement. Her clinical course was complicated by HIT, which was treated initially by danaparoid. The syndrome progressed with new thrombotic complications, and eventually was treated successfully by bivalirudin (Angiomax; Medison Pharma Ltd, Petach Tikva, Israel) for 9 days. We propose that treatment with bivalirudin for several days is a safe and effective alternative to heparin therapy in patients who develop HIT.

Original languageEnglish
Pages (from-to)331-333
Number of pages3
JournalBlood Coagulation and Fibrinolysis
Issue number4
StatePublished - 1 Jan 2006


  • Bivalirudin
  • Heparin-induced thrombocytopenia
  • Thrombosis

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Bivalirudin for anticoagulation in mechanical aortic valve replacement and heparin-induced thrombocytopenia'. Together they form a unique fingerprint.

Cite this